

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
NBG-110

In Application of: Daniela Fattori et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/554,152	October 21, 2005	Unassigned	48388	Unassigned	Unassigned

Title: NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Under 37 CFR 1.97(b) or 1.97(c)

Docket No.

NBG-110

In Re Application of: Daniela Fattori et al.

Application No. 10/554,152	Filing Date October 21, 2005	Examiner Unassigned	Customer No. 48388	Group Art Unit Unassigned	Confirmation No. Unassigned
-------------------------------	---------------------------------	------------------------	-----------------------	------------------------------	--------------------------------

Title: NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS AND FORMULATIONS CONTAINING THEM

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

June 28, 2006

(Date)

Signature of Person Mailing Correspondence

Mark D. Lorusso

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: June 28, 2006

Mark D. Lorusso
Reg. No. 41,955
LORUSSO & ASSOCIATES
3 Pinecrest Terrace
Portsmouth, NH 03801
Tel.: 603-427-0070
Fax: 603-427-5530
Email: mlorusso@lloplaw.com

CC:




PATENT
ATTORNEY'S DOCKET NO.: NBG-110

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Daniela Fattori et al.
Serial No.: 10/554,152
Filed: October 21, 2005
For: NK-2 ANTAGONIST BASIC LINEAR COMPOUNDS
AND FORMULATIONS CONTAINING THEM
Examiner: Not Assigned
Art Unit: Not Assigned

CERTIFICATE OF MAILING

I hereby certify that the following correspondence is being deposited with the United States Postal service as first class mail in an envelope addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313—1450 on June 28, 2006.


Mark D. Lorusso

Commissioner for Patents
PO BOX 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 C.F.R. §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the applicants request consideration of this information disclosure statement.

Compliance with 37 C.F.R. §1.97

This information disclosure statement has been filed before the mailing of a first office action on the merits. No fee or certification is required.

Information Cited

The applicants hereby make of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the relative importance of the references.

Remarks

Pursuant to 37 C.F.R. § 1.98(a)(2)(i), copies of non-U.S. patent references are enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

- The examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- The enclosed form PTO-1449 be signed by the examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- The citations for the information be printed on any patent which issues from this application.

By submitting this information disclosure statement, the applicants make no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this information disclosure statement, the applicants make no representation that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this information disclosure statement, the applicants make no representation that the information cited in the statement is, or is considered to be, in

fact, prior art as defined by 35 U.S.C. §102.

It is understood by applicants that the foregoing information will be considered and, to the extent deemed appropriate by the examiner, will be reflected in the examiner's communication.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Mark D. Lorusso', with a stylized flourish at the end.

Mark D. Lorusso
Reg. No. 41,955
Lorusso & Associates
15 Rye Street, Suite 312
Portsmouth, NH 03801
Tel: (603) 427-0070
Attorneys for Applicants

Docket No.: NBG-110

Date: June 28, 2006

(Use several sheets if necessary)

Application Number
10/554,152

Filing Date
October 21, 2005

Group Art Unit	Unassigned
----------------	------------

[illegible][illegible]

		D. Regoli, E. Escher, J. Mizrahi; "Substance P-Structure-Activity Studies and the Development of Antagonists" (Pharmacology 28: 301-320 (1984)).

DATE CONSIDERED

Form PTO-A820
(also form PTO-1449)

P09A/REV04

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE